Status and phase
Conditions
Treatments
About
The main purpose of this study is to investigate the safety and tolerability of ixekizumab in participants in India with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
All participants:
For PsO Participants:
For PsA Participants
Exclusion criteria
For PsO Participants:
For PsA Participants:
Primary purpose
Allocation
Interventional model
Masking
250 participants in 1 patient group
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal